The study is a single-center, non-randomized prospective study with the aim of evaluating the safety and feasibility of minimally invasive MRI-guided laser ablation (also named as Laser Interstitial Thermal Therapy or LITT) of tumor tissue in patients with glioblastoma. Glioblastoma is the most common and most aggressive form of malignant brain tumor in adults. The first five patients in the study were all diagnosed with recurrent glioblastoma.
In
The team at Skåne
Professor Peter Siesjö, who is principal investigator of the study comments, "The treatment system used for surgical intervention and navigation in the MR camera worked excellently in the completed clinical study. The benefits are obvious for the patients with less invasive interventions and shorter treatment times. For the healthcare system, the method provides the opportunity to offer treatment in cases where conventional surgery it not possible or suitable".
Regarding the future significance of the study, Peter Siesjö says the following: "As the workflow for laser ablation in the MR camera improves, and the duration of the intervention thereby decreases, the demand will increase. Laser ablation of primary and secondary brain tumors as well as epileptic foci and radiation necrosis is better for both the patient and the healthcare system. For the patient, the procedure is less invasive with a lower risk of complications, shorter treatment time and faster recovery, and for the healthcare system, the method probably means a more precise and effective treatment."
When the follow-up of the last patient is complete, in about three months, the results will be compiled, and a manuscript submitted to a scientific medical journal. The results are also planned to be used as part of an upcoming application for CE marking of the system for use in neurosurgery on the European market.
In early June, a full market launch of the ClearPoint Prism Neuro Laser Therapy System was initiated in the US through CLS' partner
For more information, please contact:
Tel: +46 - (0)705 - 90 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
For more information about CLS, please visit the Company's website: www.clinicallaser.se
https://news.cision.com/cls/r/recruitment-of-glioblastoma-patients-to-the-cls-sponsored-clinical-study-at-skane-university-hospita,c4003111
https://mb.cision.com/Main/11591/4003111/2877339.pdf
(c) 2024 Cision. All rights reserved., source